Illinois Medicaid GLP-1 Coverage (2026): The Strictest Exclusion in the Series — Doubly-Anchored on 89 IAC § 140.441(b) + HFS PDL Absence, No Wegovy Carve-Back-In

Illinois Medicaid — administered by the Illinois Department of Healthcare and Family Services (HFS) under the HealthChoice Illinois program — does NOT cover GLP-1 receptor agonists for weight loss. The exclusion is doubly anchored: (1) a state administrative regulation, 89 Ill. Adm. Code § 140.441(b), explicitly excludes “Anorectic drugs or combinations including such drugs” from pharmacy coverage, and (2) the HFS Preferred Drug List effective April 1, 2026 contains no entry for Wegovy, Zepbound, Saxenda, or Foundayo anywhere in its 7,599 lines. Illinois is the most explicitly-regulated exclusion of the six states in our 50-state Medicaid series so far — closer to New York (doubly-anchored) than to Florida or Texas (operationally silent), but stricter: no Wegovy cardiovascular pathway, no MASH pathway, no OSA pathway has been published. The regulatory text that anchors this exclusion predates the existence of modern GLP-1 weight-management drugs: it was last amended May 30, 2014 — five months before the FDA approved Saxenda (December 2014) as the first GLP-1 RA for chronic weight management, and seven years before the FDA approved Wegovy (June 2021).

What Illinois Medicaid covers (the bottom line)

As of the HFS Preferred Drug List effective April 1, 2026, Illinois Medicaid covers GLP-1 receptor agonists in a single therapeutic class: Antidiabetics: Incretin Mimetic Agents (GLP-1 Receptor Agonists), for the type 2 diabetes mellitus indication only. Coverage status for each drug (verbatim from the April 1, 2026 PDL, lines 1058–1073):

• Trulicity (dulaglutide, SOAJ): Preferred — no PA required at point of sale.
• Liraglutide (generic, SOPN): Preferred.
• Victoza (liraglutide, brand, SOPN): Preferred.
• Rybelsus (oral semaglutide, TABS): Preferred With PA — a status unique to the Illinois PDL, meaning preferred formulary placement but PA required despite that status.
• Byetta (exenatide IR, SOPN): Non-Preferred — PA required.
• Exenatide (generic, SOPN): Non-Preferred — PA required.
• Ozempic (semaglutide, SOPN): Non-Preferred — PA required.
• Mounjaro (tirzepatide, SOAJ): Non-Preferred — PA required.
• Imcivree (setmelanotide): Non-Preferred — listed under Endocrine and Metabolic Agents / Genetic Disorders class (PDL line 3312), not the GLP-1 class. PA required; the door is open for the small clinical population with confirmed POMC, PCSK1, or LEPR deficiency or Bardet-Biedl syndrome.
• Wegovy (semaglutide for chronic weight management / MACE / MASH): Not listed anywhere on the April 1, 2026 PDL. No PA pathway exists under the GLP-1 class or anywhere else in the PDL.
• Zepbound (tirzepatide for chronic weight management / OSA): Not listed anywhere on the April 1, 2026 PDL.
• Saxenda (liraglutide 3 mg for chronic weight management): Not listed anywhere on the April 1, 2026 PDL. Note: the T2D-dose liraglutide (as Victoza-equivalent) IS Preferred; that is the 1.2–1.8 mg T2D dose, not the Saxenda 3 mg obesity dose.
• Foundayo (LillyDirect tirzepatide direct-to-consumer brand): Not listed. Foundayo is a cash-pay direct-to-consumer brand from Eli Lilly that does not bill insurance; PDL status is not material to the Foundayo patient pathway.

Illinois Medicaid has not published, in any document verified for this article, a Wegovy or Zepbound coverage pathway for the FDA-approved cardiovascular event-reduction, MASH, or obstructive sleep apnea indications. Patients and providers should NOT assume Illinois will cover those indications by analogy to New York (Wegovy MACE pathway) or California (Wegovy MASH pathway). We do not promise approval for any specific patient.

Where Illinois fits in the 6-state Medicaid series

This article is the sixth installment of our verbatim-primary-source 50-state Medicaid GLP-1 series. The series has identified four distinct structural patterns:

Illinois is closest to New York in the taxonomy: both pair a federal-statute exclusion with a state-regulatory exclusion. The critical difference is that New York's 18 NYCRR § 505.3(g)(3) excludes drugs “prescribed for the treatment of obesity, except when used for the treatment of morbid obesity” — a morbid-obesity carve-out that anchors NY's Wegovy MACE pathway. Illinois's 89 Ill. Adm. Code § 140.441(b) has no such carve-out. It excludes “Anorectic drugs or combinations including such drugs” without qualification, and HFS has not published any weight-management or cardiovascular carve-back-in over that exclusion. Illinois is therefore the strictest-exclusion state in the six-state cluster.

The doubly-anchored exclusion, layer 1: 89 Ill. Adm. Code § 140.441(b)

Illinois Medicaid pharmacy coverage is governed by 89 Ill. Adm. Code Part 140 (Medical Payment), promulgated under the Illinois Public Aid Code (305 ILCS 5). Section 140.441 enumerates pharmacy services not covered. Subsection (b) reads, verbatim:

“Section 140.441 Pharmacy Services Not Covered
The following items are excluded from coverage:
[…]
b) Anorectic drugs or combinations including such drugs”

Source: Illinois Administrative Code, Title 89: Social Services, Part 140: Medical Payment, Subpart D: Payment for Non-Institutional Services, Section 140.441 (Cornell Legal Information Institute mirror). Amendment date on record: 38 Ill. Reg. 12141, effective May 30, 2014.

Why the 2014 amendment date is a load-bearing fact

The Section 140.441(b) regulatory text was written — and last amended — to cover the traditional anti-obesity drug class of the 1980s–2000s: phentermine, diethylpropion, benzphetamine, phendimetrazine, and similar Schedule III/IV appetite suppressants. The FDA approved Saxenda (liraglutide 3 mg) as the first GLP-1 receptor agonist for chronic weight management on December 23, 2014 — seven months after the May 30, 2014 amendment. Wegovy (semaglutide 2.4 mg) was FDA-approved on June 4, 2021. Zepbound (tirzepatide) was FDA-approved for chronic weight management on November 8, 2023.

The regulatory text does not specifically name GLP-1 receptor agonists, and HFS has not issued — in any verifiable provider notice or published interpretive guidance retrievable for this article — an explicit policy anchoring the Section 140.441(b) exclusion to GLP-1 weight-management drugs by name. What the Article writer can state with full confidence is the operational consequence: the HFS Preferred Drug List effective April 1, 2026 does not list Wegovy, Zepbound, Saxenda, or Foundayo anywhere in its 7,599 lines. That PDL absence is consistent with non-coverage regardless of which regulatory rationale is invoked — the state anorectic-drug exclusion at Section 140.441(b), the federal optional exclusion at 42 U.S.C. § 1396r-8(d)(2)(A), or the operational fact of PDL absence. We do not opine on the constitutional or administrative-law basis of any single layer.

The doubly-anchored exclusion, layer 2: 42 U.S.C. § 1396r-8(d)(2)(A)

The federal authority supporting every state Medicaid weight-loss drug exclusion is 42 U.S.C. § 1396r-8(d)(2), which enumerates categories of “excludable drugs” that states may (optionally) exclude from Medicaid coverage. Verbatim from the federal statute:

“Agents when used for anorexia, weight loss, or weight gain.”

This is permissive authority, not a federal mandate. Illinois elects to use this optional exclusion, operationalized through 89 Ill. Adm. Code § 140.441(b) and the absence of weight-management GLP-1 brands from the HFS PDL. Illinois is NOT among the 13 state Medicaid programs the KFF January 2026 tracker identifies as covering GLP-1s for obesity treatment under fee-for-service. Illinois did not appear on KFF's earlier October 2025 tracker either, consistent with the state's longstanding regulatory exclusion — not a coverage rollback, but a state that never covered this indication.

HFS Preferred Drug List (April 1, 2026): verbatim GLP-1 entries

The Illinois HFS PDL (effective April 1, 2026) uses three explicit status columns: Preferred, Preferred With PA, and Non-Preferred. Verbatim from PDL page 1:

“Drug Class | Drug Name | Dosage Form | Preferred | Preferred With PA | Non-Preferred”

The complete verbatim GLP-1 T2D class listings (lines 1058–1073, PDL pages 24–25):

The Preferred / Non-Preferred inversion: Illinois vs TX / FL / NY

Illinois's T2D GLP-1 PDL configuration stands out across the series. In Texas and Florida, Ozempic and Mounjaro are typically Preferred; in New York, Ozempic is BLTG-Preferred and Mounjaro is Non-Preferred. In Illinois: Ozempic and Mounjaro are both Non-Preferred— PA required for both — while the Preferred set is Trulicity (dulaglutide), liraglutide (generic), and Victoza (liraglutide brand). Rybelsus occupies a third status (“Preferred With PA”) that exists in the Illinois PDL but has no exact analog in the other state PDLs reviewed in this series.

For patients already on Ozempic or Mounjaro for T2D under a prior commercial insurance plan who transition to Illinois Medicaid, this means PA is required even for the T2D indication — and the prescriber will need to document why Trulicity or liraglutide (the Preferred options) are not clinically appropriate before Ozempic or Mounjaro can be approved.

Illinois is unique in this series: in-house PBMS, not a contracted external PBM

Illinois HFS administers fee-for-service Medicaid pharmacy claims through an in-house Pharmacy Benefit Management System (PBMS) integrated with the Illinois MMIS / IMPACT system. Verbatim from the HFS Provider Notice of March 4, 2025:

“While the Pharmacy Benefit Management System (PBMS) prior authorization system is pending restoration, HFS strongly encourages prescribers to prescribe and pharmacies to fill using drugs from the PDL as clinically appropriate.”

Verbatim from the ILLINOIS Rx Portal page:

“The ILLINOIS Rx Portal is part of the Illinois MMIS system upgrade. The ILLINOIS Rx Portal gives prescribers and pharmacies quick and secure web-access for processing and managing pharmacy benefits.”

Per the HFS PDL Background page, the clinical review function — the analysis presented to the Drugs and Therapeutics Advisory Board (DTAB) to support PDL recommendations — is contracted to the University of Illinois at Chicago College of Pharmacy:

“[The DTAB is] a board comprised of practicing clinicians representing various specialties who actively participate in the Medicaid Program”

“[whose] review and recommendations are based on evidence-based clinical information, not cost”

“If these factors indicate no therapeutic advantage among the drugs being considered in the same drug class, then HFS considers the net economic impact”

This in-house architecture contrasts with every other state in this series:

The practical implication: when the Change Healthcare nationwide outage struck on February 21, 2024, it disrupted the IL Medicaid PBMS because Change Healthcare provided upstream claims-clearinghouse components — NOT because Change Healthcare was the IL Medicaid PBM itself. The HFS Provider Notice of March 25, 2024 confirmed claims processing was restored on March 23, 2024. There is no external pharmacy benefit manager of record for IL HFS fee-for-service pharmacy claims.

HealthChoice Illinois MCOs and plan-level PDL deferral

Approximately 80% of Illinois Medicaid spending flows through managed-care organizations (MCOs) under capitated contracts, per the Illinois Auditor General 2023 PBM Performance Audit (Senate Resolution 792). The active HealthChoice Illinois MCO roster (as of January 1, 2026):

• Aetna Better Health of Illinois — PBM: CVS Caremark (per IL Auditor 2023, page 8: “In November 2018, CVS acquired Aetna. CVS Caremark serves as [the PBM]”). Formulary primary-source page returned HTTP 403 to programmatic agents in this article's verifier session; GLP-1 weight-management coverage is presumed to follow the HFS state PDL absence. Aetna Member Services: 1-866-329-4701.
• Blue Cross Community Health Plans (BCCHP, BCBSIL) — PBM: Prime Therapeutics, LLC (per IL Auditor 2023: “Blue Cross Blue Shield — Prime Therapeutics serves as the PBM for Blue [Cross Community Health Plan]”).
• CountyCare Health Plan (Cook County only) — PBM: MedImpact (per IL Auditor 2023: “CountyCare — The MCO is contracted with MedImpact as its PBM, with MedImpact Direct as ‘a non-dispensing mail order pharmacy.’”). CountyCare's provider page also references CVS Caremark for PA workflows; the Auditor 2023 data window predates any potential PBM transition, so readers should treat CountyCare's own published provider page as the operative current source for PA workflows.
• Meridian Health Plan (Centene) — PBM: MeridianRx + Prime Therapeutics (per IL Auditor 2023: “MeridianRx and Prime Therapeutics [are] the PBM subcontractors for Meridian”). Also administers YouthCare HealthChoice Illinois (former DCFS youth-in-care specialty plan).
• Molina Healthcare of Illinois — PBM: CVS Caremark (per IL Auditor 2023: “Molina — CVS Caremark serves as the PBM for Molina”). Formulary primary-source page returned Akamai bot-block in this article's verifier session; Molina Member Services: 1-855-687-7861.

Strongest plan-level deferral: CountyCare verbatim

CountyCare's provider-facing PDL page states, verbatim:

“CountyCare maintains a Preferred Drug List (PDL), the same PDL as HealthChoice Illinois and all Medicaid Health Plans in Illinois.”

“CountyCare requires prior authorization for select drugs on the PDL as well as ALL drugs not on the PDL.”

This is the strongest plan-level deferral language found in this verifier session: an explicit statement that all HealthChoice MCOs share the HFS PDL. Because Wegovy, Zepbound, Saxenda, and Foundayo are absent from the HFS PDL, they are absent from CountyCare's coverage as well.

Clearest plan-level categorical exclusion: BCBSIL BCCHP verbatim

The BCBSIL Blue Cross Community Health Plans Formulary (List of Drugs, effective April 1, 2025) states the following categorical drug exclusions verbatim on page 1 (“Which drug categories are not covered by the plan drug list?”):

“The following drug categories are not covered by your plan:
• Anorexia, weight loss or weight gain drugs
• Bulk chemicals
• Cosmetic enhancing drugs
• Diagnostic agents
• Drug Efficacy Study Implementation (DESI) that are classified as ineffective
• Experimental and investigational drugs
• Erectile dysfunction drugs prescribed to treat impotence
• Fertility drugs
• General anesthetic drugs
• Over-the-counter products not otherwise included on the plan’s drug list
• Surgical supply/medical devices
• Medications considered ‘unreasonable, unnecessary, and/or excessive’ according to the standards of Medicaid, clinical practice guidelines and FDA labeling.”

This is the most direct, categorical, plan-published exclusion of weight-loss drugs found in this entire 6-state series. The BCCHP formulary explicitly lists “Anorexia, weight loss or weight gain drugs” alongside fertility and cosmetic drug exclusions, leaving no ambiguity about the plan's coverage posture.

For T2D GLP-1s, BCCHP's formulary reflects the same Preferred / Non-Preferred split as the HFS state PDL: Trulicity, liraglutide/Victoza, and Rybelsus are Preferred (PA required for Rybelsus); Ozempic and Mounjaro are Non-Preferred. Wegovy, Zepbound, and Saxenda are not listed anywhere in the 11,130-line BCCHP formulary — consistent with the verbatim categorical exclusion above.

YMYL caution: what the Meridian / YouthCare PDL update notices actually say

The Meridian Illinois PDL Updates page lists Wegovy, Saxenda, and Zepbound by brand name alongside utilization-management restriction notices. It is important that patients and prescribers do NOT misread these listings as coverage authorizations. The notices, verbatim:

“07/30/24: GLP-1 receptor agonists (diabetes medication) – New limit

Impacted Medication:
[… Ozempic, Mounjaro, Saxenda (Weight Management), Wegovy (Weight Mngmt), Zepbound (Weight Mngmt) …]

Restricted to one medication (GLP-1 receptor agonists) per month”

“01/27/25: GLP1 – New Limit

GLP1s are restricted to a max of 31-day supply”

These notices establish utilization-management (UM) edits, NOT coverage authorizations for the weight-management indication. In Medicaid PDL operational practice, UM edits at the pharmacy point of sale apply to drugs the plan can be billed for under any indication. The same molecule — semaglutide, tirzepatide, liraglutide — appears under both T2D brand names (Ozempic, Mounjaro, Victoza) and weight-management brand names (Wegovy, Zepbound, Saxenda). The “restricted to one GLP-1 receptor agonist per month” rule is most coherently read as preventing concurrent fills of (for example) Ozempic and Mounjaro for the same patient — a T2D-formulary concurrent-use restriction — NOT as authorizing weight-management coverage of Wegovy or Saxenda independent of the 89 Ill. Adm. Code § 140.441(b) anorectic exclusion and the 42 U.S.C. § 1396r-8(d)(2)(A) federal optional exclusion.

Members and providers seeking weight-management coverage under Meridian or YouthCare should NOT infer that Wegovy, Saxenda, or Zepbound is reimbursed for the weight-loss indication absent an explicit Meridian coverage statement — which this article's verifier session did not locate. Call Meridian Member Services at 1-888-362-3368 for a definitive MCO-level determination.

The T2D indication vs the weight-management indication: a critical distinction

Several GLP-1 receptor agonists are FDA-approved under separate drug-brand labels for type 2 diabetes and for chronic weight management, using different doses and different FDA-approved indications:

• Semaglutide: Ozempic (T2D, up to 2 mg weekly) is Non-Preferred on the Illinois HFS PDL (PA required for T2D). Wegovy (weight management, 2.4 mg weekly) is absent from the PDL.
• Tirzepatide: Mounjaro (T2D, up to 15 mg weekly) is Non-Preferred on the Illinois HFS PDL (PA required for T2D). Zepbound (weight management, up to 15 mg weekly) is absent from the PDL.
• Liraglutide: Victoza / liraglutide generic (T2D, up to 1.8 mg daily) is Preferred on the Illinois HFS PDL. Saxenda (weight management, 3 mg daily) is absent from the PDL.

A prescriber cannot circumvent Illinois Medicaid's weight-management exclusion by prescribing Wegovy for “cardiovascular risk reduction” or Zepbound for “obstructive sleep apnea” — neither non-weight-management pathway for those drugs has been published in any HFS document verified for this article. The PDL is silent on all three non-weight-management indications for Wegovy and Zepbound. Case-by-case clinical PA review under the HFS PBMS is theoretically possible for any non-PDL drug with a documented non-weight-management FDA-approved indication, but HFS has not operationalized a Wegovy-MACE, Wegovy-MASH, or Zepbound-OSA pathway analogous to the published criteria that exist in New York (MACE) or California (MASH).

What the advisory boards have (and have not) considered

The Illinois Drug Utilization Review Advisory Board (DURAB), at its January 30, 2025 meeting, formally flagged the following as a Board-suggested future DUR topic (verbatim from meeting minutes):

“GLP-1 RA inhibitors for obstructive sleep apnea”

Also suggested at the same meeting:

“New diabetes guidelines updating what medications should be used first line”

These were Board-suggested future DUR topics, not coverage decisions. The Board did not act on either suggestion at the January 2025 meeting. The Drugs and Therapeutics Advisory Board (DTAB) — the body that recommends Preferred Drug List changes to HFS — did not address GLP-1 weight-management coverage in the meeting minutes verified for this article (August 1, 2024 and July 10, 2025). We do not predict legislative or advisory-board outcomes.

The within-state disparity: state employees vs Medicaid recipients

One of the most notable structural features of Illinois's GLP-1 landscape is a legally-documented within-state coverage asymmetry: state government employees are mandated to receive GLP-1 weight-management coverage; Medicaid recipients are not.

Illinois enacted 5 ILCS 375/6.11c (effective July 1, 2024), which requires the Illinois State Employees Group Insurance Program (administered by the Department of Central Management Services under the State Employees Group Insurance Act of 1971, 5 ILCS 375) to cover injectable GLP-1 medications including Wegovy, Mounjaro, and Ozempic for state employees diagnosed with prediabetes, gestational diabetes, or obesity. Per Capitol News Illinois reporting, the statute requires members to “participate in a lifestyle management plan administered by their health plan” to qualify; it does not extend to “the 3.9 million low-income and disabled Illinoisans enrolled in Medicaid.”

Note: The primary-source statutory text of 5 ILCS 375/6.11c at ilga.gov returned HTTP 404 in this article's verifier session. The above characterization is based on Capitol News Illinois and Becker's Payer Issues secondary reporting and is cited accordingly. Readers seeking the verbatim statutory text should visit ilga.gov and search for 5 ILCS 375/6.11c.

5 ILCS 375 governs the State Employees Group Insurance Program, NOT Illinois Medicaid. Illinois Medicaid is governed by the Illinois Public Aid Code (305 ILCS 5) and 89 Ill. Adm. Code Part 140. The 5 ILCS 375/6.11c state-employee mandate does not extend Wegovy / Mounjaro / Ozempic coverage to Medicaid recipients. This is a documented legal asymmetry within Illinois — different populations on different statutory frameworks, with materially different coverage outcomes for the same drugs.

HB 3335: the procedurally-dormant 2025 cost-cap bill

Illinois House Bill 3335 (Rep. Thaddeus Jones, 104th General Assembly) was introduced February 18, 2025. The bill's core operative provision (verbatim from Section 22 of the as-introduced bill text, page 8):

“A group or individual plan of accident and health insurance or managed care plan amended, delivered, issued, or renewed on or after January 1, 2026 that provides coverage for prescription insulin drugs shall limit the total amount that an insured is required to pay for a 30-day supply of covered prescription weight loss drugs, such as Ozempic, Wegovy, and Moujaro [sic], to an amount not to exceed $200, regardless of the quantity or type of covered prescription weight loss drug used to fill the insured’s prescription.”

(Note: “Moujaro” is a misspelling of “Mounjaro” verbatim from the as-introduced bill text.) The bill amended the Illinois Insurance Code (adding new 215 ILCS 5/356z.80) and expressly extended the cost-cap requirement to the Illinois Public Aid Code via 305 ILCS 5/5-16.8 — i.e., Illinois Medicaid was within the bill's scope. On March 21, 2025, the bill was re-referred to the Rules Committee under House Rule 19(a) — the standard parliamentary mechanism by which Illinois House leadership deactivates a bill without explicitly killing it. As of this article's compilation date (May 2026), HB 3335 has not been reported out of the Rules Committee.

Critical scope note: HB 3335 was a cost-sharing cap bill, NOT a coverage mandate bill. The $200 cap would apply to drugs a plan's coverage already includes. For Illinois Medicaid, where 89 Ill. Adm. Code § 140.441(b) excludes anorectic drugs and the HFS PDL does not list Wegovy / Zepbound / Saxenda, HB 3335 would have had no operational effect on Medicaid weight-management coverage — the $200 cap applies only where underlying coverage exists. We do not predict legislative outcomes or timeline for potential revival of HB 3335.

CMS BALANCE Model: Illinois participation status not verified

The CMS Innovation Center's BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model opened a voluntary state Medicaid agency opt-in window from May 2026 through January 1, 2027. Drug coverage under the BALANCE Model would include Mounjaro, Ozempic, Rybelsus, Wegovy, and Zepbound KwikPen for both T2D and weight-management indications in participating states. Whether Illinois HFS has submitted a notice of intent to participate is NOT verified in any primary source captured for this article. We do not represent Illinois as a BALANCE Model participant.

Patient action steps for Illinois Medicaid members

Given the doubly-anchored exclusion and the absence of any published weight-management carve-back-in pathway in Illinois Medicaid as of May 2026, the realistic coverage options for a patient seeking Wegovy, Zepbound, or Saxenda under Illinois Medicaid are limited. Here is the practical guidance:

1. Confirm your T2D status. If you have a confirmed type 2 diabetes diagnosis, the T2D-indicated GLP-1s (Ozempic for semaglutide, Mounjaro for tirzepatide, or Trulicity / liraglutide / Victoza as Preferred agents) are coverable with PA. Ask your prescriber to document your T2D diagnosis, HbA1c values, and prior diabetes medication history to support the PA submission to your MCO or the HFS PBMS.
2. Check your MCO formulary directly. Call your MCO member-services line to confirm whether your specific plan has any supplemental coverage or PA pathway beyond the HFS state PDL. Aetna Better Health: 1-866-329-4701. BCCHP: 1-877-860-2837. CountyCare: 1-312-864-8200. Meridian / YouthCare: 1-888-362-3368. Molina: 1-855-687-7861.
3. Ask your prescriber about Imcivree (setmelanotide) if you have a genetic-cause obesity. Imcivree is Non-Preferred on the Illinois HFS PDL, which means PA is required but coverage is at least possible for the small population with confirmed POMC, PCSK1, or LEPR deficiency or Bardet-Biedl syndrome. A specialist referral and confirmed genetic testing are typically required.
4. Explore manufacturer patient assistance programs. Novo Nordisk's NovoCare program offers Wegovy at $0 or $25 per month to qualifying uninsured or underinsured patients (income thresholds apply). Eli Lilly's Lilly Insulin Value Program covers Zepbound and Mounjaro for eligible patients. These programs operate independently of Medicaid coverage.
5. Check the 5 ILCS 375/6.11c state-employee coverage if applicable. If you or a family member are enrolled in the Illinois State Employees Group Insurance Program (not Medicaid), the 5 ILCS 375/6.11c mandate effective July 1, 2024 may cover injectable GLP-1s with lifestyle management plan enrollment. Contact your Department of Central Management Services benefits coordinator.
6. Consider cash-pay options at reduced rates. Foundayo (oral orforglipron, FDA-approved April 1, 2026) is a direct-to-consumer brand from Eli Lilly at $149/month at LillyDirect, available without insurance involvement. This is not Medicaid-covered but may be accessible to patients whose primary concern is cost rather than insurance billing.

Illinois fair hearing / appeal pathway

Illinois Medicaid PA decisions are subject to appeal through the HFS Bureau of Administrative Hearings. Patients who receive a PA denial for a GLP-1 medication have the right to request a fair hearing. Key procedural points:

• Request the denial notice in writing. The denial notice (Notice of Action) should state the specific regulatory or PDL basis for the denial and the deadline for requesting a hearing.
• File a fair hearing request within the stated deadline (typically 60 days from the NOA date) with the HFS Bureau of Administrative Hearings. Contact HFS at 1-800-843-6154 or visit hfs.illinois.gov for current hearing procedures.
• Understand the policy-level limitation. A fair hearing can correct adjudication errors — for example, a denial based on a misread diagnosis code or incorrect prior-fill calculation. It cannot overturn a policy-level determination. Where Wegovy, Zepbound, and Saxenda are excluded as a matter of Illinois Medicaid policy under 89 Ill. Adm. Code § 140.441(b) and the HFS PDL absence, a fair hearing will not produce a different outcome absent a change in that underlying policy.
• Legal aid organizations in Illinois (such as the Legal Aid Chicago and Prairie State Legal Services) can provide free representation in Medicaid fair hearing proceedings for qualifying low-income patients.

Related research

• Pennsylvania Medicaid GLP-1 coverage 2026: the policy reversal — Anchor #7 in the 50-state series and the only other state in the cluster with a documented YMYL trap on Non-Preferred PDL listings. PA's Wegovy and Zepbound appear as Non-Preferred in the January 2026 v8 Statewide PDL — exactly as Wegovy and Zepbound appear in Meridian/YouthCare's utilization-management update tables in Illinois. In both cases the drug appears in a formulary context for covered non-obesity indications, not as obesity-indication coverage. PA is also strictly more permissive than Illinois on non-obesity GLP-1 pathways: PA has published Wegovy MACE, MASH, and Zepbound OSA criteria; Illinois has published none.
• Texas Medicaid GLP-1 coverage + STAR+PLUS PA pathway (2026) — Anchor #1 in the 50-state series. Explicit non-coverage documented through the Acentra Jan 30, 2026 PDL Criteria Guide and the Superior HealthPlan June 2023 “Non-Covered Benefit” provider notice. Texas and Illinois share the same coverage outcome (no weight-management GLP-1 coverage) but different documentation depth: Texas has explicit MCO-level “Non-Covered Benefit” framing; Illinois has a state administrative-regulation hook.
• California Medi-Cal GLP-1 coverage (2026): the state reversal — Anchor #2. California previously covered Wegovy + Zepbound + Saxenda for weight management, removed them January 1, 2026 via the enacted state budget, then re-added Wegovy April 1, 2026 for noncirrhotic MASH only (ICD-10-CM K76.0 / K75.8). The contrast with Illinois is sharp: California reversed course; Illinois has never covered the weight-management indication.
• New York Medicaid (NYRx) GLP-1 coverage and Wegovy MACE pathway (2026) — Anchor #3 and Illinois's structural twin in the series. NY is doubly-anchored (federal statute + state regulation 18 NYCRR § 505.3(g)(3)) AND includes a morbid-obesity carve-out that Illinois lacks. NY has published a Wegovy MACE pathway (BMI ≥ 40 + CVD + lifetime 2-attempt cap); Illinois has not. Reading NY alongside IL reveals what a state-regulation-anchored exclusion looks like with and without a coverage carve-back-in.
• Florida Medicaid (AHCA SMMC) GLP-1 coverage (2026) — Anchor #4. Florida's exclusion is operationally silent — PDL absence with no single AHCA bulletin labeling Wegovy / Zepbound “Non-Covered.” Illinois is stronger-documented: it has both the HFS PDL absence AND the 89 Ill. Adm. Code § 140.441(b) regulatory text.
• GLP-1 insurance coverage across Medicare, Medicaid, and commercial plans — the federal-state coverage framework, KFF state tracker, and how Wegovy / Zepbound / Foundayo actually flow through Medicare Part D and state Medicaid programs.
• GLP-1 insurance dropped coverage appeal playbook — the four-phase appeal logic that applies directly to HFS PBMS PA denials, with the HFS Bureau of Administrative Hearings fair-hearing process substituted for the commercial-plan internal-appeal pathway.
• Cigna GLP-1 prior-authorization guide — verbatim IP0206 / CNF 684 / CNF 360 coverage policies for Illinois residents covered by Cigna commercial plans or Cigna Medicare Advantage, independent of Illinois Medicaid.
• Aetna GLP-1 prior-authorization guide — verbatim commercial-plan PA policies relevant to Illinois residents enrolled in Aetna commercial plans (distinct from Aetna Better Health of Illinois Medicaid).
• Wegovy alternatives 2026 — for Illinois Medicaid members denied weight-management coverage who are evaluating Zepbound, Foundayo, Saxenda, and the cash-pay landscape.
• GLP-1 prior-authorization letter generator — generates a Letter of Medical Necessity template that can be tailored for HFS PBMS PA submissions and HFS Bureau of Administrative Hearings fair hearing requests.
• Michigan Medicaid GLP-1 coverage (2026): Pattern #10 — partial retainment with morbid-obesity gate + bariatric-surgery-avoidance prescriber attestation — The closest structural comparator to Illinois in the 10-state cluster. Both states impose the tightest effective gates for weight-management GLP-1 access: Illinois through a pre-GLP-1-era administrative regulation (89 Ill. Adm. Code § 140.441(b), last amended May 30, 2014) with no pathway at any BMI; Michigan through Public Act 22 of 2025 appropriations boilerplate that retains a narrow morbid-obesity carve-out (BMI ≥ 40) with the uniquely Michigan bariatric-surgery-avoidance prescriber attestation found in no other state. Illinois has no MASH, MACE, or OSA carve-back-in; Michigan has all three. The contrast shows the structural difference between a standing regulatory exclusion and an appropriations-statute-driven restriction.